Wuhan Hiteck Biological Pharma Co Ltd (300683) - Net Assets

Latest as of September 2025: CN¥2.24 Billion CNY ≈ $328.35 Million USD

Based on the latest financial reports, Wuhan Hiteck Biological Pharma Co Ltd (300683) has net assets worth CN¥2.24 Billion CNY (≈ $328.35 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.64 Billion ≈ $385.87 Million USD) and total liabilities (CN¥393.09 Million ≈ $57.52 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Wuhan Hiteck Biological Pharma Co Ltd to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥2.24 Billion
% of Total Assets	85.09%
Annual Growth Rate	22.67%
5-Year Change	39.81%
10-Year Change	304.12%
Growth Volatility	45.5

Wuhan Hiteck Biological Pharma Co Ltd - Net Assets Trend (2013–2024)

This chart illustrates how Wuhan Hiteck Biological Pharma Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 300683 total asset value for the complete picture of this company's asset base.

Annual Net Assets for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)

The table below shows the annual net assets of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024. For live valuation and market cap data, see market value of Wuhan Hiteck Biological Pharma Co Ltd.

Year	Net Assets	Change
2024-12-31	CN¥2.41 Billion ≈ $352.89 Million	-3.36%
2023-12-31	CN¥2.50 Billion ≈ $365.17 Million	+6.87%
2022-12-31	CN¥2.34 Billion ≈ $341.71 Million	-0.34%
2021-12-31	CN¥2.34 Billion ≈ $342.86 Million	+35.83%
2020-12-31	CN¥1.72 Billion ≈ $252.41 Million	-2.02%
2019-12-31	CN¥1.76 Billion ≈ $257.61 Million	+2.98%
2018-12-31	CN¥1.71 Billion ≈ $250.17 Million	+4.04%
2017-12-31	CN¥1.64 Billion ≈ $240.44 Million	+133.61%
2016-12-31	CN¥703.35 Million ≈ $102.92 Million	+17.86%
2015-12-31	CN¥596.76 Million ≈ $87.32 Million	+11.21%
2014-12-31	CN¥536.59 Million ≈ $78.52 Million	+110.72%
2013-12-31	CN¥254.64 Million ≈ $37.26 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Wuhan Hiteck Biological Pharma Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 160.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥370.10 Million	15.47%
Common Stock	CN¥130.89 Million	5.47%
Other Components	CN¥1.89 Billion	79.05%
Total Equity	CN¥2.39 Billion	100.00%

Wuhan Hiteck Biological Pharma Co Ltd Competitors by Market Cap

The table below lists competitors of Wuhan Hiteck Biological Pharma Co Ltd ranked by their market capitalization.

Company	Market Cap
HELLOFRESH UNSP.ADS/025 F:HFG0	$677.03 Million
Beijing Tianyishangjia New Material Corp Ltd SHG:688033	$677.06 Million
Yujin Robot Co. Ltd KQ:056080	$677.48 Million
Addnode Group AB (publ) ST:ANOD-B	$677.70 Million
Samsung Fire And Marine Ins Pref KO:000815	$676.84 Million
Vor Biopharma Inc NASDAQ:VOR	$676.54 Million
Nufarm Ltd AU:NUF	$676.41 Million
Sok Marketler Ticaret As IS:SOKM	$676.37 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Wuhan Hiteck Biological Pharma Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 2,478,155,270 to 2,391,790,341, a change of -86,364,929 (-3.5%).
Net loss of 69,348,658 reduced equity.
Dividend payments of 1,761,277 reduced retained earnings.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥-69.35 Million	-2.9%
Dividends Paid	CN¥1.76 Million	-0.07%
Other Changes	CN¥-15.25 Million	-0.64%
Total Change	CN¥-	-3.49%

Book Value vs Market Value Analysis

This analysis compares Wuhan Hiteck Biological Pharma Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.93x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 8.96x to 1.93x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2013-12-31	CN¥3.94	CN¥35.34	x
2014-12-31	CN¥7.73	CN¥35.34	x
2015-12-31	CN¥7.79	CN¥35.34	x
2016-12-31	CN¥9.01	CN¥35.34	x
2017-12-31	CN¥18.96	CN¥35.34	x
2018-12-31	CN¥16.43	CN¥35.34	x
2019-12-31	CN¥16.95	CN¥35.34	x
2020-12-31	CN¥16.53	CN¥35.34	x
2021-12-31	CN¥21.85	CN¥35.34	x
2022-12-31	CN¥18.92	CN¥35.34	x
2023-12-31	CN¥19.07	CN¥35.34	x
2024-12-31	CN¥18.28	CN¥35.34	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Wuhan Hiteck Biological Pharma Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -2.90%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -10.69%
• Asset Turnover: 0.22x
• Equity Multiplier: 1.23x
Recent ROE (-2.90%) is below the historical average (8.08%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	30.68%	21.81%	0.81x	1.74x	CN¥52.34 Million
2014	20.56%	20.03%	0.68x	1.50x	CN¥56.46 Million
2015	13.98%	12.27%	0.78x	1.46x	CN¥23.74 Million
2016	22.54%	20.37%	0.74x	1.49x	CN¥87.37 Million
2017	8.70%	18.98%	0.39x	1.17x	CN¥-21.25 Million
2018	5.54%	15.93%	0.27x	1.27x	CN¥-75.82 Million
2019	3.60%	10.16%	0.29x	1.24x	CN¥-112.19 Million
2020	-1.46%	-4.77%	0.24x	1.28x	CN¥-195.89 Million
2021	1.19%	4.50%	0.23x	1.16x	CN¥-204.79 Million
2022	-0.61%	-2.04%	0.25x	1.17x	CN¥-245.07 Million
2023	-4.88%	-20.06%	0.20x	1.20x	CN¥-368.64 Million
2024	-2.90%	-10.69%	0.22x	1.23x	CN¥-308.53 Million

Industry Comparison

This section compares Wuhan Hiteck Biological Pharma Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $1,347,197,696
Average return on equity (ROE) among peers: 4.46%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Wuhan Hiteck Biological Pharma Co Ltd (300683)	CN¥2.24 Billion	30.68%	0.18x	$676.90 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$2.84 Billion	-41.97%	9.13x	$1.22 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$638.89 Million	0.88%	0.70x	$438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$1.05 Billion	10.46%	0.19x	$5.18 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.07 Billion	3.83%	0.46x	$2.81 Billion
Wedge Industrial Co Ltd (000534)	$1.29 Billion	11.69%	1.47x	$2.95 Billion
Yunnan Baiyao Group Co Ltd (000538)	$35.11 Million	18.13%	0.80x	$13.85 Billion
Hainan Haiyao Co Ltd (000566)	$5.08 Billion	1.71%	1.08x	$949.23 Million
Tus Pharmaceutical Group Co Ltd (000590)	$141.91 Million	11.01%	0.32x	$391.07 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$994.58 Million	2.01%	2.11x	$1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$332.48 Million	26.89%	0.68x	$3.30 Billion

About Wuhan Hiteck Biological Pharma Co Ltd

SHE:300683 China Drug Manufacturers - Specialty & Generic

Market Cap

$676.90 Million

CN¥4.63 Billion CNY

Market Cap Rank

#11014 Global

#3267 in China

Share Price

CN¥35.34

Change (1 day)

+0.26%

52-Week Range

CN¥22.83 - CN¥59.56

All Time High

CN¥84.19